Commentary on "Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma" by B. J. Kennedy, Jane L. Torkelson, and Elwin E. Fraley in this issue pp. 541-545.
Kagan
A R
AR
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D012074:Remission Induction; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D014747:Vinblastine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin